Kathleen Kemmer
Biochemistry, Genetics and Molecular Biology · University of Michigan
Publications
44
Citations
4,497
Est. group size
~1
Recurring co-author estimate
Active years
35
Publishing since 1992
Typically publishes in teams of ~43 · 0% small-team papers (≤3 authors) · across 11 venues
- Durvalumab with olaparib and paclitaxel for high-risk HER2-negative stage II/III breast cancer: Results from the adaptively randomized I-SPY2 trial
Cancer Cell · 2021
- Assessment of Residual Cancer Burden and Event-Free Survival in Neoadjuvant Treatment for High-risk Breast Cancer
JAMA Oncology · 2021
- Neoadjuvant T-DM1/pertuzumab and paclitaxel/trastuzumab/pertuzumab for HER2+ breast cancer in the adaptively randomized I-SPY2 trial
Nature Communications · 2021
- Ganitumab and metformin plus standard neoadjuvant therapy in stage 2/3 breast cancer
npj Breast Cancer · 2021
- Effect of Pembrolizumab Plus Neoadjuvant Chemotherapy on Pathologic Complete Response in Women With Early-Stage Breast Cancer
JAMA Oncology · 2020
- Association of Event-Free and Distant Recurrence–Free Survival With Individual-Level Pathologic Complete Response in Neoadjuvant Treatment of Stages 2 and 3 Breast Cancer
JAMA Oncology · 2020
- MK-2206 and Standard Neoadjuvant Chemotherapy Improves Response in Patients With Human Epidermal Growth Factor Receptor 2–Positive and/or Hormone Receptor–Negative Breast Cancers in the I-SPY 2 Trial
Journal of Clinical Oncology · 2020
- Abstract CT011: Evaluation of durvalumab in combination with olaparib and paclitaxel in high-risk HER2 negative stage II/III breast cancer: Results from the I-SPY 2 TRIAL
Cancer Research · 2020
- Abstract P3-09-02: Evaluation of a novel agent plus standard neoadjuvant therapy in early stage, high-risk HER2 negative breast cancer: Results from the I-SPY 2 TRIAL
Cancer Research · 2020
- Durvalumab With Olaparib and Paclitaxel for High-Risk HER2-Negative Stage II/III Breast Cancer: Results From the Adaptively Randomized I-SPY2 Platform Trial
SSRN Electronic Journal · 2020
- Early Prediction of Breast Cancer Therapy Response using Multiresolution Fractal Analysis of DCE-MRI Parametric Maps
Tomography · 2019
- Abstract P2-09-03: Updated efficacy of first or second-line pembrolizumab (pembro) plus capecitabine (cape) in metastatic triple negative breast cancer (mTNBC) and correlations with baseline lymphocyte and naïve CD4+ T-cell count
Cancer Research · 2019
- A phase II trial of olaparib and durvalumab in metastatic BRCA wild type triple-negative breast cancer.
Journal of Clinical Oncology · 2019
- Abstract CT136: Evaluation of talazoparib in combination with irinotecan in early stage, high-risk HER2 negative breast cancer: Results from the I-SPY 2 TRIAL
Cancer Research · 2019
- Abstract CT136: Evaluation of talazoparib in combination with irinotecan in early stage, high-risk HER2 negative breast cancer: Results from the I-SPY 2 TRIAL
Clinical Trials · 2019
- Cancer Research×9
- Journal of Clinical Oncology×6
- JAMA Oncology×3
- npj Breast Cancer×3
- New England Journal of Medicine×2
- Kai Johnson
Biochemistry, Genetics and Molecular Biology · The Ohio State University
- Mathew Cherian
Biochemistry, Genetics and Molecular Biology · The Ohio State University
- Julie Stephens
Biochemistry, Genetics and Molecular Biology · The Ohio State University
- Nicole Williams
Biochemistry, Genetics and Molecular Biology · The Ohio State University
- Arya Mariam Roy
Biochemistry, Genetics and Molecular Biology · The Ohio State University
This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.
Last updated Jul 25, 2026.
Claim or correct this profile